&nbsp;

plansPrintBtnIconPurple.png

Oct 2019

Document

pdfWhite.png

Oct 2019

Document

pdfWhite1.png

Oct 2019

Document

pdfWhite2.png

Oct 2019

Document

pdfWhite3.png

Oct 2019

Regimen

PERT+TRAS

Cancer Type:

Breast

Intent: Adjuvant, Curative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

PERTuzumab (Unfunded),

trastuzumab

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

AC-PACL(W)+PERT+TRAS

Cancer Type:

Breast

Intent: Curative, Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

DOXOrubicin,

cyclophosphamide,

PACLitaxel,

PERTuzumab (Unfunded),

trastuzumab

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

AC-PACL(DD)+PERT+TRAS

Cancer Type:

Breast

Intent: Curative, Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

DOXOrubicin,

cyclophosphamide,

PACLitaxel,

PERTuzumab (Unfunded),

trastuzumab

Quick Link(s):

Regimen Monograph

Sep 2022

Statistical Reports

About This Report

Statistical Reports

Analysis

Document

PancreaticCancerIREInformationForPatients.pdf

Dec 2019

Regimen

AXIT+PEMB

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

aXitinib - In combination with pembrolizumab for first-line advanced or metastatic renal cell carcinoma

New Drug Funding Program

Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma

Drugs Used:

aXitinib,

pembrolizumab